Alnylam Pharmaceuticals shares are trading lower. The company announced results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy.
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals' shares are declining following the announcement of results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for ATTR amyloidosis with cardiomyopathy.
August 30, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alnylam Pharmaceuticals' stock is experiencing a decline due to the announcement of results from the HELIOS-B Phase 3 study of vutrisiran, which is being developed for ATTR amyloidosis with cardiomyopathy.
The decline in Alnylam's stock price is likely due to investor reaction to the results of the HELIOS-B Phase 3 study. Such announcements can significantly impact biotech stocks, especially if the results do not meet investor expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100